Literature DB >> 28442394

Granin-derived peptides.

Josef Troger1, Markus Theurl2, Rudolf Kirchmair2, Teresa Pasqua3, Bruno Tota3, Tommaso Angelone3, Maria C Cerra3, Yvonne Nowosielski4, Raphaela Mätzler4, Jasmin Troger4, Jaur R Gayen5, Vance Trudeau6, Angelo Corti7, Karen B Helle8.   

Abstract

The granin family comprises altogether 7 different proteins originating from the diffuse neuroendocrine system and elements of the central and peripheral nervous systems. The family is dominated by three uniquely acidic members, namely chromogranin A (CgA), chromogranin B (CgB) and secretogranin II (SgII). Since the late 1980s it has become evident that these proteins are proteolytically processed, intragranularly and/or extracellularly into a range of biologically active peptides; a number of them with regulatory properties of physiological and/or pathophysiological significance. The aim of this comprehensive overview is to provide an up-to-date insight into the distribution and properties of the well established granin-derived peptides and their putative roles in homeostatic regulations. Hence, focus is directed to peptides derived from the three main granins, e.g. to the chromogranin A derived vasostatins, betagranins, pancreastatin and catestatins, the chromogranin B-derived secretolytin and the secretogranin II-derived secretoneurin (SN). In addition, the distribution and properties of the chromogranin A-derived peptides prochromacin, chromofungin, WE14, parastatin, GE-25 and serpinins, the CgB-peptide PE-11 and the SgII-peptides EM66 and manserin will also be commented on. Finally, the opposing effects of the CgA-derived vasostatin-I and catestatin and the SgII-derived peptide SN on the integrity of the vasculature, myocardial contractility, angiogenesis in wound healing, inflammatory conditions and tumors will be discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Betagranin; Catestatin; Chromacin; Chromogranin A; Chromogranin B; EM66; GE-25; Homeostatic regulations; Inflammatory conditions; Inhibition of tumor growth; Innate immunity; Manserin; Multifunctional effects; Myocardial protections; Pancreastatin; Parastatin; Prochromacin; Proteolytic processing; Secretogranin II; Secretolytin; Secretoneurin; Serpinins; Vascular integrity; Vasostatin-I; Vasostatin-II; WE-14

Mesh:

Substances:

Year:  2017        PMID: 28442394     DOI: 10.1016/j.pneurobio.2017.04.003

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  20 in total

Review 1.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

2.  Short-Term Administration of Common Anesthetics Does Not Dramatically Change the Endogenous Peptide Profile in the Rat Pituitary.

Authors:  Somayeh Mousavi; Haowen Qiu; Frazer I Heinis; Md Shadman Ridwan Abid; Matthew T Andrews; James W Checco
Journal:  ACS Chem Neurosci       Date:  2022-09-20       Impact factor: 5.780

3.  Phosphopeptidomics Reveals Differential Phosphorylation States and Novel SxE Phosphosite Motifs of Neuropeptides in Dense Core Secretory Vesicles.

Authors:  Christopher B Lietz; Thomas Toneff; Charles Mosier; Sonia Podvin; Anthony J O'Donoghue; Vivian Hook
Journal:  J Am Soc Mass Spectrom       Date:  2018-03-19       Impact factor: 3.109

4.  Targeted mutation of secretogranin-2 disrupts sexual behavior and reproduction in zebrafish.

Authors:  Kimberly Mitchell; Wo Su Zhang; Chunyu Lu; Binbin Tao; Lu Chen; Wei Hu; Vance L Trudeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-28       Impact factor: 11.205

5.  Catestatin serum levels are increased in male patients with obstructive sleep apnea.

Authors:  Josip A Borovac; Zoran Dogas; Daniela Supe-Domic; Tea Galic; Josko Bozic
Journal:  Sleep Breath       Date:  2018-08-07       Impact factor: 2.816

6.  Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling.

Authors:  Md Jahangir Alam; Richa Gupta; Nitish R Mahapatra; Shyamal K Goswami
Journal:  Mol Cell Biochem       Date:  2019-12-02       Impact factor: 3.396

Review 7.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

8.  Peptidomics of enteroendocrine cells and characterisation of potential effects of a novel preprogastrin derived-peptide on glucose tolerance in lean mice.

Authors:  Sam G Galvin; Pierre Larraufie; Richard G Kay; Haidee Pitt; Elise Bernard; Anne K McGavigan; Helen Brant; John Hood; Laura Sheldrake; Shannon Conder; Dawn Atherton-Kemp; Van B Lu; Elisabeth A A O'Flaherty; Geoffrey P Roberts; Carina Ämmälä; Lutz Jermutus; David Baker; Fiona M Gribble; Frank Reimann
Journal:  Peptides       Date:  2021-03-17       Impact factor: 3.750

Review 9.  The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.

Authors:  Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

10.  Chromogranin A pathway: from pathogenic molecule to renal disease.

Authors:  Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2020-03       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.